Literature DB >> 8138523

Clozapine treatment in very early onset schizophrenia.

T Mozes1, P Toren, N Chernauzan, R Mester, R Yoran-Hegesh, R Blumensohn, A Weizman.   

Abstract

Very early onset schizophrenic patients only partially benefit from conventional antipsychotic treatment and are at increased risk for developing tardive dyskinesia (TD). Clozapine, which lacks extrapyramidal side effects including TD, has been proved effective for adult schizophrenic patients who are resistant to other neuroleptics. Clozapine, therefore, may offer an alternative treatment for these patients. The authors report four successful trials of clozapine in children aged 10 to 12 years old with schizophrenia, the youngest group reported on to date, who were unresponsive to conventional neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138523     DOI: 10.1097/00004583-199401000-00010

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  14 in total

1.  Management of clozapine-induced fever in a child.

Authors:  David I Driver; Afsoon A Anvari; Christina M Peroutka; Rachna Kataria; Jerry Overman; David Lang; Maria Tietcheu; Reggie Parker; Keith Baptiste; Judith L Rapoport; Nitin Gogtay
Journal:  Am J Psychiatry       Date:  2014-04       Impact factor: 18.112

2.  Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Markus Mittendorf; Frank M Theisen; Karin Wolf-Ostermann; Phillip Grant; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-04-28       Impact factor: 4.785

Review 3.  Children with schizophrenia: clinical picture and pharmacological treatment.

Authors:  Gabriele Masi; Maria Mucci; Cinzia Pari
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Andrew T Olagunju; Scott R Clark; Bernhard T Baune
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 5.  Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment.

Authors:  Michael Poyurovsky; Abraham Weizman; Ronit Weizman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Blood biogenic amines during clozapine treatment of early-onset schizophrenia.

Authors:  E Schulz; C Fleischhaker; H W Clement; H Remschmidt
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 7.  Tolerability profile of atypical antipsychotics in children and adolescents.

Authors:  K A Stigler; M N Potenza; C J McDougle
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 8.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 9.  Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap.

Authors:  P Tibbo; L Warneke
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

10.  Olanzapine compared to quetiapine in adolescents with a first psychotic episode.

Authors:  Celso Arango; Olalla Robles; Mara Parellada; David Fraguas; Ana Ruiz-Sancho; Oscar Medina; Arantzazu Zabala; Igor Bombín; Dolores Moreno
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-05       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.